Skip to content

Sutro Biopharma STRO Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
Xencor logo
XencorXNCR
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Roivant Sciences logo
Roivant SciencesROIV
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's accrued liabilities, current?
Sutro Biopharma (STRO) reported accrued liabilities, current of $5.35M in Q1 2026.
How has Sutro Biopharma's accrued liabilities, current changed year-over-year?
Sutro Biopharma's accrued liabilities, current decreased by 53.7% year-over-year, from $11.55M to $5.35M.
What is the long-term trend for Sutro Biopharma's accrued liabilities, current?
Over 5 years (2020 to 2025), Sutro Biopharma's accrued liabilities, current has grown at a 10.7% compound annual growth rate (CAGR), from $8.82M to $14.64M.